bioMérieux: recovery gains momentum, with analyst's support

(CercleFinance.com) - bioMérieux shares are continuing the recovery that began the previous Friday in Paris, where, in addition to renewed market optimism, the diagnostics specialist is still benefiting from positive comments from Barclays.


After gaining more than 0.1% yesterday, the share price is now up by around 1.1%.

In a note published the previous day, Barclays analysts said they had initiated coverage of the stock with an 'overweight' recommendation and a target price of E120, representing 20% upside potential.

The broker hails the company as a 'quality player' in a growing market, notably highlighting its ability to grow thanks to its presence in multiplex tests, where demand is resisting well.

It also praised its leading position, with a market share of around 75%, in the infectious diseases segment with its Biofire platform.

Barclays, which sees the group's profit margins improving despite continued high R&D spending, says it predicts free cash flow of over E300m this year and average annual sales growth of 7% by 2027.


Copyright (c) 2024 CercleFinance.com. All rights reserved.